Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:20 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 79,237 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Recruiting Not applicable Interventional

Peru Decentralized HIV Care

NCT05910268
View directory record Official record
Conditions
HIV
Interventions
NIATx + ECHO
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 1, 2026, 5:20 AM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

NCT03637491
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avelumab, Binimetinib, Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 1Phase 2 Interventional Results available

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

NCT03112590
View directory record Official record
Conditions
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
Interventions
Interferon-gamma (IFN-γ), Paclitaxel, Trastuzumab, Pertuzumab, Post Therapy Surgery
Biological · Drug · Other + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Nov 1, 2026, 5:20 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Feasibility and Acceptability of a Single Session of Imagery Rescripting in a Community Sample of Adults

NCT06610318
View directory record Official record
Conditions
Feasibility Studies, Acceptability, Depressive Symptoms, Disordered Eating Behaviors
Interventions
imagery rescripting, nutrition education
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Nov 1, 2026, 5:20 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

7 Tesla MRI Study in Patients With Statin Related Muscle Complaints

NCT04575090
View directory record Official record
Conditions
Statin-related Muscle Pain, Muscle Aches, Muscle Weakness, Muscle Cramp, Muscle Stiffness
Interventions
Simvastatin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Nov 1, 2026, 5:20 AM EST
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797
View directory record Official record
Conditions
Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Interventions
Plixorafenib
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
8 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 1, 2026, 5:20 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin

NCT03093597
View directory record Official record
Conditions
Xerosis, Xerosis Cutis, Dry Skin; Eczema
Interventions
virgin coconut oil, virgin jojoba oil, virgin almond oil, white petrolatum ointment
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Tucson, Arizona • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Nov 1, 2026, 5:20 AM EST
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Physical Exercise for Augmenting Cognitive Health (PEACH)

NCT04922710
View directory record Official record
Conditions
Cognitive Aging, Adverse Childhood Experiences
Interventions
Home-based aerobic exercise
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
30 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Nov 1, 2026, 5:20 AM EST
Terminated Phase 2 Interventional Results available

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

NCT04003610
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 1, 2026, 5:20 AM EST
Recruiting Phase 2 Interventional

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

NCT07359820
View directory record Official record
Conditions
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Interventions
Lirafugratinib
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 1, 2026, 5:20 AM EST
Not listed No phase listed Observational

A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue

NCT05268224
View directory record Official record
Conditions
Breast Cancer Screening
Interventions
Schirmer Strip
Diagnostic Test
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

NCT02489448
View directory record Official record
Conditions
Breast Neoplasms
Interventions
MEDI4736
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 3 Interventional Results available

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)

NCT04370548
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
DARE-BV1clindamycin phosphate vaginal gel, 2%
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Nov 1, 2026, 5:20 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of a Black Rice Extract and Anthocyanidin Metabolites on the Synthesis and Release of BDNF in Healthy Subjects

NCT06594848
View directory record Official record
Conditions
Cognition - Other, Depression, Anxiety
Interventions
Black rice extract, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 1, 2026, 5:20 AM EST
Not yet recruiting Not applicable Interventional

Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness

NCT07291778
View directory record Official record
Conditions
Acute Kidney Injury, VExUS
Interventions
Fluid Management, No intervention
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 1, 2026, 5:20 AM EST
Active, not recruiting Phase 1 Interventional

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT05479578
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8
Interventions
Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Rashmi Verma, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Nov 1, 2026, 5:20 AM EST
Not listed Not applicable Interventional

Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes

NCT05826678
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitor, Finger stick glucose monitoring
Device · Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 3 Interventional Results available

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

NCT01709578
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
56
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Nov 1, 2026, 5:20 AM EST
Completed No phase listed Observational

Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2

NCT02526485
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Blood Draw
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance
Interventions
exenatide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Nov 1, 2026, 5:20 AM EST
Suspended Not applicable Interventional

Adding Specialist Palliative Care to Transplantation Pilot Trial

NCT05147935
View directory record Official record
Conditions
End Stage Liver DIsease
Interventions
Palliative Care Consultation
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 5:20 AM EST
Terminated Phase 3 Interventional

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

NCT00741715
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AVE5530, atorvastatin, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Pistachios Blood Sugar Control, Heart and Gut Health

NCT04056208
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Diseases
Interventions
Pistachio, Usual care
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Nov 1, 2026, 5:20 AM EST
Completed Not applicable Interventional

Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes

NCT02301325
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Smoking research cigarettes with or without NRT
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Nov 1, 2026, 5:20 AM EST